-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Acadia Pharmaceuticals, Lowers Price Target to $36

Benzinga·10/08/2026 13:59:29
语音播报
RBC Capital analyst Brian Abrahams maintains Acadia Pharmaceuticals (NASDAQ:ACAD) with a Outperform and lowers the price target from $37 to $36.